Kite Pharma Inc. (KITE) 57.67 $KITE
Health Care IPO Filings Moving Into A Busy New Year
at Investor's Business Daily - Wed Dec 31, 3:04PM CST
The market for health care IPOs is continuing its hot pace into the new year. In the last three days, seven companies in the sector have filed to go public. The largest of the initial public offerings just filed is Inovalon, which provides...
RDUS: 38.91 (+0.95), IMS: 25.64 (-0.32), KITE: 57.67 (+1.73), ASPX: 52.48 (+1.95), JUNO: 52.22 (+0.84)
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Dec 30, 7:36AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the underwriters of its previously announced follow-on public offering of 3,485,000 shares of common stock have exercised in full their option to purchase an additional 522,750 shares of common stock at the public offering price of $54 per share, less customary underwriting discounts and commissions. The closing of the option exercise is expected to occur on January 2, 2015.
KITE: 57.67 (+1.73)
Billionaires Are Gobbling Up These Stocks Right Now
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 5:55AM CST
The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. According to recent 13F filings submitted to the SEC, we have...
ABT: 45.02 (-0.67), ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), KITE: 57.67 (+1.73), PFE: 31.15 (-0.23), CLDN: 19.53 (-0.11), ABBV: 65.44 (-0.86)
Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:20PM CST
Kite Pharma, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive non-Hodgkin lymphoma.
CYTK: 8.01 (+1.11), KITE: 57.67 (+1.73), MDCO: 27.67 (+0.02), AMGN: 159.29 (-1.34)
7 Best Performing IPOs of Record-Breaking 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 8:41AM CST
The US IPO market was the biggest in 2014 since 2000 in terms of both value and number.
GPRO: 63.22 (-2.18), SC: 19.61 (-0.19), GE: 25.27 (-0.30), IM: 27.64 (-0.06), ALLY: 23.62 (-0.15), FB: 78.02 (-1.20), RBS: 12.11 (+0.05), AKR: 32.03 (-0.59), CBD: 36.83 (-0.16), RDUS: 38.91 (+0.95), V: 262.20 (-2.35), KITE: 57.67 (+1.73), CFG: 24.86 (-0.33), SYF: 29.75 (-0.25), JD: 23.14 (-0.11), PGRE: 18.59 (-0.15), AM: 27.50 (+0.49)
Billionaire George Soros Made a Bundle on Kite Pharmaceuticals -- Will He Buy This Biotech IPO Too?
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 28, 6:47AM CST
Source: The Guardian As of the end of September, billionaire investor George Soros owned more than 660,000 shares of immunotherapy biotech stock Kite Pharmaceuticals , shares that Soros could very well have bought during Kite's IPO in July...
KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84)
Renaissance Capital's 2014 Global IPO Annual Review
Renaissance Capital IPO Research - at Seeking Alpha - Fri Dec 26, 2:18AM CST
Bolstered by Alibaba, Global IPO Issuance Surges in 2014 Supported by stable equity returns, global IPO issuance reached the highest levels since 2010. Annual IPO proceeds increased 48.7% to $204.8 billion. North America was the largest...
ZTS: 43.03 (-0.32), ECR: 7.03 (+0.25), KITE: 57.67 (+1.73), AAVL: 54.00 (-1.89), NADL: 1.63 (unch), ATEN: 4.36 (+0.15), BABA: 103.94 (-1.81)
Alibaba Tops The 5 Most Watched IPOs In Booming 2014
at Investor's Business Daily - Wed Dec 24, 2:54PM CST
This year was the best for initial public offerings since 2000 in both the number of IPOs and proceeds raised. And the IPO market shows no signs of slowing in 2015. That's a good sign for the economy, as young growth companies are a big contributor...
AMBA: 50.72 (-1.68), IMDZ: 30.78 (+0.77), GPRO: 63.22 (-2.18), LC: 25.30 (-0.53), V: 262.20 (-2.35), KITE: 57.67 (+1.73), CYBR: 39.65 (-0.20), FB: 78.02 (-1.20), TGT: 75.91 (+0.20), SNE: 20.47 (-0.11), JUNO: 52.22 (+0.84), JD: 23.14 (-0.11), AAPL: 110.38 (-2.14), BABA: 103.94 (-1.81)
Alibaba Lifts Global IPO Market To Best Year Since 2010
at Investor's Business Daily - Wed Dec 24, 2:46PM CST
The global IPO market raised $204.8 billion in proceeds in 2014, up 49% from 2013 and the most since 2010, led by the $21.8 billion Alibaba (BABA) offering. Initial public offerings worldwide totaled 375, up 24% and also the most since 2010, reports...
KITE: 57.67 (+1.73), CFG: 24.86 (-0.33), AAVL: 54.00 (-1.89), SYF: 29.75 (-0.25), BABA: 103.94 (-1.81)
Kite Pharma submits IND for blood cancer candidate
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 12:26PM CST
KITE: 57.67 (+1.73)
Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma
GlobeNewswire - Mon Dec 22, 11:40AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 1/2 study of KTE-C19, the Company's investigational anti-CD19 CAR T cell therapy, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL).
KITE: 57.67 (+1.73)
Can You Guess the Best-Performing Biotech IPO of 2014? (Hint: Shares Rallied 217%)
Todd Campbell, The Motley Fool - Motley Fool - Mon Dec 22, 6:04AM CST
Biotech stocks are no strangers to big moves, but Kite Pharma 's 217% return since its IPO in Juneis still pretty eye-popping. The company, which is developing innovative immunotherapy treatments for cancer, went public at $17 and has rallied to...
PCYC: 122.26 (-0.32), KITE: 57.67 (+1.73)
Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
at The Street - Mon Dec 22, 5:14AM CST
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
ESRX: 84.67 (-1.08), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), GILD: 94.26 (-1.02), JUNO: 52.22 (+0.84), ABBV: 65.44 (-0.86), NVS: 92.66 (-0.55)
Cramer's Mad Money - Look At Red Hat Go (12/19/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 21, 4:26AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 19. CEO Interview, James Whitehurst, Red Hat (NYSE: RHT ) "Look at Red Hat ( RHT ) run." The stock dominates Open Source software for...
BLUE: 91.72 (-1.08), GPRO: 63.22 (-2.18), AVP: 9.39 (-0.10), SYNA: 68.84 (-0.68), NKE: 96.15 (-0.73), SKX: 55.25 (-0.67), DECK: 91.04 (-0.82), DIS: 94.19 (-0.51), CSIQ: 24.19 (+0.54), PAYX: 46.17 (-0.69), RDNT: 8.54 (-0.65), KITE: 57.67 (+1.73), RHT: 69.14 (-0.34), HAWK: 38.80 (-0.75), JUNO: 52.22 (+0.84), PAY: 37.20 (-0.11), WAG: 76.05 (-0.49)
Juno Therapeutics IPO Caps Big Year In Biotech Deals
at Investor's Business Daily - Fri Dec 19, 11:47AM CST
Juno Therapeutics (JUNO) set a record as the most highly valued biotech IPO this year, with the stock jumping 62% as trading began Friday. The initial public offering raised $265 million, with the company selling 11 million shares at 24. Juno...
IMDZ: 30.78 (+0.77), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), IMGN: 6.10 (+0.08), JUNO: 52.22 (+0.84)
Bellicum Leaps On Biotech IPO, Setting Stage For Juno
at Investor's Business Daily - Thu Dec 18, 11:44AM CST
Capping what has been a big year for biotech IPOs, Bellicum Pharmaceuticals (BLCM) bolted on its public debut Thursday, with Juno Therapeutics coming next. Bellicum raised $140 million by offering 7.35 million shares at 19, above its 15-17 range....
BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84)
Juno Therapeutics: Saving The Best Biotech IPO For Last In 2014
Chris Katje - at Seeking Alpha - Wed Dec 17, 10:13AM CST
BLUE: 91.72 (-1.08), KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84)
Juno Therapeutics Ups IPO Price In Hot Biotech Field
at Investor's Business Daily - Tue Dec 16, 1:46PM CST
Juno Therapeutics (JUNO), which is developing cutting-edge treatments for cancer, raised the expected price of its initial public offering, indicating strong demand for shares of the biotech company. Juno now looks to raise $203.5 million, up from...
IMDZ: 30.78 (+0.77), JPM: 62.58 (-0.57), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), C: 54.11 (-0.73), JUNO: 52.22 (+0.84), MS: 38.80 (-0.20)
Kite Pharma Added to the NASDAQ Biotechnology Index
GlobeNewswire - Tue Dec 16, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI), which will become effective upon market open on Monday, December 22, 2014.
KITE: 57.67 (+1.73), IBB: 303.35 (-1.27)
IPO Calendar: Year Wrapping Up With Juno, OnDeck IPOs
at Investor's Business Daily - Mon Dec 15, 4:46PM CST
Four IPOs scheduled this week are expected to raise $923 million and likely will be the last new issues of 2014, the hottest year for initial public offerings since 2000. OnDeck Capital (ONDK), which provides an online platform for small-business...
LC: 25.30 (-0.53), SAP: 69.65 (-0.75), ONDK: 22.43 (-0.04), RICE: 20.97 (-0.73), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84), RMP: 16.75 (+0.71), GOOGL: 530.66 (-4.62)
Health Care IPO Filings Moving Into A Busy New Year
at Investor's Business Daily - Wed Dec 31, 3:04PM CST
The market for health care IPOs is continuing its hot pace into the new year. In the last three days, seven companies in the sector have filed to go public. The largest of the initial public offerings just filed is Inovalon, which provides...
RDUS: 38.91 (+0.95), IMS: 25.64 (-0.32), KITE: 57.67 (+1.73), ASPX: 52.48 (+1.95), JUNO: 52.22 (+0.84)
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Dec 30, 7:36AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the underwriters of its previously announced follow-on public offering of 3,485,000 shares of common stock have exercised in full their option to purchase an additional 522,750 shares of common stock at the public offering price of $54 per share, less customary underwriting discounts and commissions. The closing of the option exercise is expected to occur on January 2, 2015.
KITE: 57.67 (+1.73)
Billionaires Are Gobbling Up These Stocks Right Now
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 5:55AM CST
The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. According to recent 13F filings submitted to the SEC, we have...
ABT: 45.02 (-0.67), ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), KITE: 57.67 (+1.73), PFE: 31.15 (-0.23), CLDN: 19.53 (-0.11), ABBV: 65.44 (-0.86)
Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:20PM CST
Kite Pharma, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive non-Hodgkin lymphoma.
CYTK: 8.01 (+1.11), KITE: 57.67 (+1.73), MDCO: 27.67 (+0.02), AMGN: 159.29 (-1.34)
7 Best Performing IPOs of Record-Breaking 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 8:41AM CST
The US IPO market was the biggest in 2014 since 2000 in terms of both value and number.
GPRO: 63.22 (-2.18), SC: 19.61 (-0.19), GE: 25.27 (-0.30), IM: 27.64 (-0.06), ALLY: 23.62 (-0.15), FB: 78.02 (-1.20), RBS: 12.11 (+0.05), AKR: 32.03 (-0.59), CBD: 36.83 (-0.16), RDUS: 38.91 (+0.95), V: 262.20 (-2.35), KITE: 57.67 (+1.73), CFG: 24.86 (-0.33), SYF: 29.75 (-0.25), JD: 23.14 (-0.11), PGRE: 18.59 (-0.15), AM: 27.50 (+0.49)
Billionaire George Soros Made a Bundle on Kite Pharmaceuticals -- Will He Buy This Biotech IPO Too?
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 28, 6:47AM CST
Source: The Guardian As of the end of September, billionaire investor George Soros owned more than 660,000 shares of immunotherapy biotech stock Kite Pharmaceuticals , shares that Soros could very well have bought during Kite's IPO in July...
KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84)
Renaissance Capital's 2014 Global IPO Annual Review
Renaissance Capital IPO Research - at Seeking Alpha - Fri Dec 26, 2:18AM CST
Bolstered by Alibaba, Global IPO Issuance Surges in 2014 Supported by stable equity returns, global IPO issuance reached the highest levels since 2010. Annual IPO proceeds increased 48.7% to $204.8 billion. North America was the largest...
ZTS: 43.03 (-0.32), ECR: 7.03 (+0.25), KITE: 57.67 (+1.73), AAVL: 54.00 (-1.89), NADL: 1.63 (unch), ATEN: 4.36 (+0.15), BABA: 103.94 (-1.81)
Alibaba Tops The 5 Most Watched IPOs In Booming 2014
at Investor's Business Daily - Wed Dec 24, 2:54PM CST
This year was the best for initial public offerings since 2000 in both the number of IPOs and proceeds raised. And the IPO market shows no signs of slowing in 2015. That's a good sign for the economy, as young growth companies are a big contributor...
AMBA: 50.72 (-1.68), IMDZ: 30.78 (+0.77), GPRO: 63.22 (-2.18), LC: 25.30 (-0.53), V: 262.20 (-2.35), KITE: 57.67 (+1.73), CYBR: 39.65 (-0.20), FB: 78.02 (-1.20), TGT: 75.91 (+0.20), SNE: 20.47 (-0.11), JUNO: 52.22 (+0.84), JD: 23.14 (-0.11), AAPL: 110.38 (-2.14), BABA: 103.94 (-1.81)
Alibaba Lifts Global IPO Market To Best Year Since 2010
at Investor's Business Daily - Wed Dec 24, 2:46PM CST
The global IPO market raised $204.8 billion in proceeds in 2014, up 49% from 2013 and the most since 2010, led by the $21.8 billion Alibaba (BABA) offering. Initial public offerings worldwide totaled 375, up 24% and also the most since 2010, reports...
KITE: 57.67 (+1.73), CFG: 24.86 (-0.33), AAVL: 54.00 (-1.89), SYF: 29.75 (-0.25), BABA: 103.94 (-1.81)
Kite Pharma submits IND for blood cancer candidate
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 12:26PM CST
KITE: 57.67 (+1.73)
Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma
GlobeNewswire - Mon Dec 22, 11:40AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 1/2 study of KTE-C19, the Company's investigational anti-CD19 CAR T cell therapy, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL).
KITE: 57.67 (+1.73)
Can You Guess the Best-Performing Biotech IPO of 2014? (Hint: Shares Rallied 217%)
Todd Campbell, The Motley Fool - Motley Fool - Mon Dec 22, 6:04AM CST
Biotech stocks are no strangers to big moves, but Kite Pharma 's 217% return since its IPO in Juneis still pretty eye-popping. The company, which is developing innovative immunotherapy treatments for cancer, went public at $17 and has rallied to...
PCYC: 122.26 (-0.32), KITE: 57.67 (+1.73)
Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
at The Street - Mon Dec 22, 5:14AM CST
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
ESRX: 84.67 (-1.08), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), GILD: 94.26 (-1.02), JUNO: 52.22 (+0.84), ABBV: 65.44 (-0.86), NVS: 92.66 (-0.55)
Cramer's Mad Money - Look At Red Hat Go (12/19/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 21, 4:26AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 19. CEO Interview, James Whitehurst, Red Hat (NYSE: RHT ) "Look at Red Hat ( RHT ) run." The stock dominates Open Source software for...
BLUE: 91.72 (-1.08), GPRO: 63.22 (-2.18), AVP: 9.39 (-0.10), SYNA: 68.84 (-0.68), NKE: 96.15 (-0.73), SKX: 55.25 (-0.67), DECK: 91.04 (-0.82), DIS: 94.19 (-0.51), CSIQ: 24.19 (+0.54), PAYX: 46.17 (-0.69), RDNT: 8.54 (-0.65), KITE: 57.67 (+1.73), RHT: 69.14 (-0.34), HAWK: 38.80 (-0.75), JUNO: 52.22 (+0.84), PAY: 37.20 (-0.11), WAG: 76.05 (-0.49)
Juno Therapeutics IPO Caps Big Year In Biotech Deals
at Investor's Business Daily - Fri Dec 19, 11:47AM CST
Juno Therapeutics (JUNO) set a record as the most highly valued biotech IPO this year, with the stock jumping 62% as trading began Friday. The initial public offering raised $265 million, with the company selling 11 million shares at 24. Juno...
IMDZ: 30.78 (+0.77), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), IMGN: 6.10 (+0.08), JUNO: 52.22 (+0.84)
Bellicum Leaps On Biotech IPO, Setting Stage For Juno
at Investor's Business Daily - Thu Dec 18, 11:44AM CST
Capping what has been a big year for biotech IPOs, Bellicum Pharmaceuticals (BLCM) bolted on its public debut Thursday, with Juno Therapeutics coming next. Bellicum raised $140 million by offering 7.35 million shares at 19, above its 15-17 range....
BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84)
Juno Therapeutics: Saving The Best Biotech IPO For Last In 2014
Chris Katje - at Seeking Alpha - Wed Dec 17, 10:13AM CST
BLUE: 91.72 (-1.08), KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84)
Juno Therapeutics Ups IPO Price In Hot Biotech Field
at Investor's Business Daily - Tue Dec 16, 1:46PM CST
Juno Therapeutics (JUNO), which is developing cutting-edge treatments for cancer, raised the expected price of its initial public offering, indicating strong demand for shares of the biotech company. Juno now looks to raise $203.5 million, up from...
IMDZ: 30.78 (+0.77), JPM: 62.58 (-0.57), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), C: 54.11 (-0.73), JUNO: 52.22 (+0.84), MS: 38.80 (-0.20)
Kite Pharma Added to the NASDAQ Biotechnology Index
GlobeNewswire - Tue Dec 16, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI), which will become effective upon market open on Monday, December 22, 2014.
KITE: 57.67 (+1.73), IBB: 303.35 (-1.27)
IPO Calendar: Year Wrapping Up With Juno, OnDeck IPOs
at Investor's Business Daily - Mon Dec 15, 4:46PM CST
Four IPOs scheduled this week are expected to raise $923 million and likely will be the last new issues of 2014, the hottest year for initial public offerings since 2000. OnDeck Capital (ONDK), which provides an online platform for small-business...
LC: 25.30 (-0.53), SAP: 69.65 (-0.75), ONDK: 22.43 (-0.04), RICE: 20.97 (-0.73), BLCM: 23.04 (+0.04), KITE: 57.67 (+1.73), JUNO: 52.22 (+0.84), RMP: 16.75 (+0.71), GOOGL: 530.66 (-4.62)
